A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Metabolic Disease Research

Background:

• Antiangiogenesis is a therapeutic strategy for obesity, but its efficacy in nanoparticle-targeted treatments for obesity comorbidities remains unclear.
• Diet-induced obesity (DIO) and metabolic syndrome are linked to dysfunctional adipose tissue and ectopic fat deposition.

Purpose of the Study:

• To investigate the therapeutic potential of prohibitin-targeted nanoparticles (PTNP) loaded with a proapoptotic peptide (KLA) for treating DIO and associated metabolic dysfunction.
• To evaluate the efficacy of KLA-PTNP compared to Adipotide in reducing body weight and improving adipose tissue health.

Main Methods:

• Systemic injection of KLA-PTNP into DIO mice.
• Assessment of body weight, serum leptin and adiponectin levels.
• Analysis of adipose tissue, including adipocytes and macrophages.
• Evaluation of ectopic fat deposition in liver and muscle.
• Assessment of hepatotoxicity.

Main Results:

• KLA-PTNP treatment significantly reduced body weight and serum leptin levels in DIO mice.
• Dysfunctional adipose cells (adipocytes and macrophages) showed an anti-obesity effect.
• Ectopic fat deposits in the liver and muscle were reduced, associated with increased serum adiponectin.
• Nanoparticle delivery was enhanced by active targeting and endosomal escape, with no detectable hepatotoxicity.

Conclusions:

• Vascular-targeted nanotherapy using KLA-PTNP demonstrates a positive effect on diet-induced obesity and metabolic syndrome.
• This approach effectively targets dysfunctional adipose tissue, reduces ectopic fat, and improves metabolic parameters without causing liver toxicity.
• Nanoparticle-mediated delivery holds potential for controlling adipose function and ectopic fat deposition in obesity management.